To find a reference on this page either scroll or hold down the "Ctrl" key and press "f".
|
Cabaser
|
| see cabergoline 23(3) 64-7 |
|
cabergoline
|
| Cabaser (New strength) 23(3) 64-7 |
| cabergoline-induced valvulopathy (medicinal mishap) 31(1) 21 |
| hyperprolactinaemia - Dostinex (New drug) 19(1) 24-7 |
|
caesarian section
|
| carbetocin - prevention of uterine atony - Duratocin (New drug) 30(4) 107-11 |
|
caffeine
|
| distribution in human milk 20(2) 35-40 |
| guarana preparations (letter) 21(1) 5-8 |
|
Calcijex
|
| see calcitriol 19(2) 38-40 |
|
calcineurin inhibitors
|
| pharmacology of immunosuppressants 29(4) 99-101; 29(4) 102-8 |
|
calcipotriol
|
| Daivonex (New formulation) - correction 25(2) 44-7 |
| Diavonex (New formulation) 24(6) 155-8 |
| psoriasis - Daivonex (New drug) 17(3) 73 |
|
calcitriol
|
| new formulation - Calcijex 19(2) 38-40 |
|
calcium channel antagonists
|
| clinical pharmacology 20(1) 5-8 |
| dihydropyridines and nocturia 20(1) 3-4 |
| distribution in human milk 20(2) 35-40 |
| gingival enlargement 26(1) 11-3 |
| in hypertension in diabetes 25(1) 8-10 |
| letter 25(3) 51-3 |
| lercanidipine - Zanidip (New drug) 24(6) 155-8 |
| mibefradil - Posicor (New drug) 21(2) 49-55 |
| nifedipine and gingival hyperplasia (letter) 17(1) 4-5 |
| and risk of myocardial infarction (editorial) 22(1) 2-3; 19(2) 35 |
|
calcium chloride
|
| management of cardiac arrest 20(2) 41-5 |
|
calcium gluconate
|
| management of cardiac arrest 20(2) 41-5 |
|
calcium supplementation
|
| osteoporosis 26(6) 126-7 |
| letter 27(4) 82-3 |
|
calcium, dietary
|
| renal calculi 19(4) 94-7 |
|
Campral
|
| see acamprosate 22(6) 147-51 |
|
Camptosar
|
| see irinotecan 21(2) 49-55 |
|
Canada
|
| Ontario drug costs policies 25(6) 128-30 |
|
cancer (see also antineoplastics and specific organs)
|
| angiogenesis inhibitors - pharmacology 29(1) 9-12; 29(1) 13-5 |
| antiemetic in chemotherapy - tropisetron - Navoban (New drug) 17(4) 87-90 |
| Book review - Cancer Facts - a concise oncology text 23(2) 42 |
| chemotherapy and cancer survival rates (editorial) 29(1) 2-3 |
| iobenguane - MIBGen - adrenal tumour localisation (New drug) 27(5) 131-3 |
| morphine and methadone in palliative care (letter) 23(5) 93-6 |
| neurocognitive effects of chemotherapy 31(1) 22-4 |
| oral mucositis prevention in chemotherapy - palifermin - Kepivance (New drug) 28(6) 156-8 |
| palliative care for non-malignant disease 26(5) 98-9 |
| patient information 19(2) 55 |
| radiotherapy and xerostomia 29(4) 97-8 |
| dental notes 29(4) 108 |
| letters 30(1) 3-4 |
| risks with hormone replacement in menopause (letter) 17(1) 4-5 |
| thyrotropin alfa-rch - thyroid cancer diagnosis - Thyrogen (New drug) 24(6) 155-8 |
| zoledronic acid - tumour-induced hypercalcaemia - Zometa (New drug) 25(1) 20-3 |
|
cancer chemotherapy - see antineoplastics
|
|
Cancer Facts
|
| a concise oncology text - book review 23(2) 42 |
|
Cancidas
|
| see caspofungin acetate 25(6) 147-51 |
|
candesartan
|
| antihypertensive - Atacand (New drug) 22(1) 20-3 |
|
candidiasis
|
| antifungal drugs 19(3) 72-5 |
| butoconazole nitrate - Gynazole - candidal vulvovaginitis (New drug) 29(5) 138-43 |
| genital - management 24(3) 59-61; 24(3) 62-4 |
|
Candyl
|
| see piroxicam 18(1) 7-9 |
|
Candyl D
|
| see piroxicam 19(3) 81-3 |
|
cannabis
|
| distribution in human milk 20(2) 35-40 |
|
capecitabine
|
| breast cancer - Xeloda (New drug) 22(4) 95-8 |
| capsular polysaccharide typhoid vaccine - Typhim Vi (New drug) 17(2) 30-2 |
| captopril (New brand) 23(1) 21-3 |
| colorectal cancer 25(5) 108-10; 25(5) 111-3 |
|
carbamazepine
|
| in bipolar disorders 30(3) 70-3 |
| Carbium (New brand) 22(6) 147-51 |
| clinical use of antiepileptics 17(1) 9-12 |
| in neuropathic pain 22(6) 140-1 |
| toxicity 25(3) 73-4 |
| letter 25(5) 104-7 |
|
carbapenem antibiotics
|
| ertapenem - Invanz (New drug) 25(4) 94-9 |
| meropenem - Merrem IV (New drug) 20(2) 45-51 |
|
carbetocin
|
| Duratocin - prevention of uterine atony after caesarian section (New drug) 30(4) 107-11 |
|
Carbium
|
| see carbamazepine 22(6) 147-51 |
|
carbonic anhydrase inhibitors
|
| dorzolamide - glaucoma - Trusopt Eye Drops (New drug) 20(2) 45-51 |
| in glaucoma 25(6) 142-6 |
|
carcinoembryonic antigen
|
| arcitumomab - colorectal cancer immunoscintigraphy - CEA-Scan (New drug) 26(3) 68-71 |
|
carcinoma, basal cell
|
| methyl-5-aminolevulinate - Metvix (New drug) 27(3) 76-9 |
|
carcinoma, renal cell - see renal cell carcinoma
|
|
cardiac arrest
|
| cardiac troponins 24(3) 56-8 |
| management 20(2) 41-5 |
| letters 21(3) 60-3; 20(4) 83-6 |
|
cardiac troponins
|
| cardiac markers 24(3) 56-8 |
| abnormal laboratory results 26(4) 88-90 |
|
cardiovascular disease
|
| ACE inhibitors vs diuretics 27(4) 98-101 |
| antiretroviral therapy in HIV infection 28(6) 146-9 |
| diabetes 25(1) 8-10 |
| exercise 30(5) 130-3 |
| echocardiography 29(5) 134-8 |
| letter 30(1) 3-4 |
| editorial 23(1) 2 |
| hypertension management 26(3) 53-5 |
| letters |
| NSAIDs in rheumatology (editorial) 29(4) 90-1 |
| the polypill controversy (editorial) 28(4) 82-3 |
| risks and hormone replacement therapy 26(1) 8-10; 23(5) 90-2 |
| Therapeutic Guidelines - book review 26(6) 125 |
| and travel 23(5) 107-9 |
|
cardiovascular medicine
|
| in the 21st century (editorial) 23(1) 2 |
|
cardiovascular system
|
| dopamine clinical pharmacology 17(2) 42-3 |
|
Cardizem
|
| see diltiazem 24(1) 20-3; 23(5) 110-1 |
|
Carduran
|
| see doxazocin 18(4) 86-7 |
|
CARPA Standard Treatment Manual
|
| book review 27(1) 8 |
|
carvedilol
|
| in heart failure 23(6) 120-3 |
| Kredex, Dilatrend (New drug) 21(3) 80-3 |
|
caspofungin acetate
|
| aspergillosis - Cancidas (New drug) 25(6) 147-51 |
|
catheters
|
| infection control 26(2) 41-3 |
| letter 26(4) 75-7 |
|
Caverject
|
| see alprostadil 18(3) 58-9 |
|
CEA-Scan
|
| see arcitumomab 26(3) 68-71 |
|
cefaclor
|
| Aclor (New brand) 27(1) 21-3 |
| GenRx cefaclor (New brand) 24(1) 20-3 |
| Karlor (New brand) 27(5) 131-3 |
| Keflor (New brand) 20(3) 77-9 |
| and serum sickness (letter) 22(2) 28-31 |
|
Cefalexin-BC
|
| see cephalexin 25(6) 147-51; 25(4) 94-9 |
|
Cefazolin
|
| see cephazolin 27(6) 159-65 |
|
cefepime
|
| injectable cephalosporin - Maxipime (New drug) 21(3) 80-3 |
| intravenous cephalosporin - Cefrom (New drug) 18(2) 35-8 |
|
cefotaxime
|
| DBL cefotaxime (New brand) 24(6) 155-8 |
|
cefpodoxime proxetil
|
| new formulation - Orelox 19(3) 81-3 |
| oral cephalosporin - Orelox (New drug) 17(3) 73 |
|
Cefrom
|
| see cefpirome 18(2) 35-8 |
|
ceftriaxone
|
| Ceftriaxone-BC (New brand) 24(4) 100-2 |
|
Celapram
|
| see citalopram 27(1) 21-3 |
|
celecoxib
|
| pharmacology of COX inhibitors 23(2) 30-2 |
| prescriptions and adverse effects (PBAC question) 24(1) 7-8 |
| correction 24(3) 64 |
| vascular effects of COX-2 selective inhibitors 27(6) 142-5 |
| letter 28(2) 29-33 |
|
celery seed tablets
|
| thyroxine interactions 24(1) 6-7 |
|
cell markers
|
| abnormal laboratory results 30(5) 128-9 |
|
CellCept
|
| see mycophenolate mofetil 23(3) 64-7; 20(2) 45-51 |
|
cellulitis, ocular
|
| management 17(3) 66-8 |
| in renal calculi 19(4) 94-7 |
|
cephalexin
|
| Cefalexin-BC (New brand) 25(6) 147-51; 25(4) 94-9 |
| Ialex (New brand) 27(5) 131-3 |
|
cephalosporins
|
| cefepime - Maxipime (New drug) 21(3) 80-3 |
| cefpirome sulfate - Cefrom (New drug) 18(2) 35-8 |
| cefpodoxime - Orelox (New drug) 17(3) 73 |
| penicillin allergy 30(1) 25-6 |
| prescribing improvements in hospitals 24(2) 29-31 |
| in sinusitis (letter) 23(6) 115-7 |
|
cephazolin
|
| cefazolin (New formulation) 27(6) 159-65 |
| new brand - Cephazolin 20(1) 22-3 |
|
Ceprotin
|
| see protein C 30(2) 50-55 |
|
cerebral aneurysm
|
| tirilazad mesylate - subarachnoid haemorrhage - Freedox (New drug) 20(2) 45-51 |
|
cerebrovascular disorders
|
| antiplatelet drugs 19(4) 104-8 |
| beta blockers in hypertension 30(1) 5-7 |
| letter 30(3) 59-63 |
| cerebrovascular imaging (editorial) 24(6) 134 |
| magnetic resonance angiography 24(6) 141-3 |
| ultrasound 24(6) 137-40 |
| clopidogrel - antiplatelet drug - Plavix (New drug) 22(2) 43-7 |
| consensus conference 22(4) 85-7 |
| early management of acute stroke 27(5) 120-3 |
| magnetic resonance imaging in neuroradiology 31(1) 18-20 |
| positron emission tomography 18(1) 15-8 |
|
Ceredase
|
| see alglucerase 18(1) 7-9 |
|
Cerezyme
|
| see imiglucerase 22(4) 95-8 |
|
cerivastatin
|
| gemfibrozil combination and rhabdomyolysis 24(5) 109 |
| hypercholesterolaemia 22(5) 114-7 |
| Lipobay (New drug) 22(4) 95-8 |
| Lipobay (New strength) 24(2) 43-7 |
|
Certican
|
| see everolimus 28(3) 75-9 |
|
Cervarix
|
| human papillomavirus vaccine 30(5) 133-5 |
|
cervical cancer
|
| human papillomavirus vaccine - Cervarix (New drug) 30(5) 133-5 |
| human papillomavirus vaccine - Gardasil (New drug) 29(5) 138-43 |
|
cetirizine
|
| Zyrtec (New formulation) 21(4) 108-11 |
|
cetrorelix
|
| assisted reproduction - Cetrotide (New drug) 24(6) 155-8 |
|
Cetrotide
|
| see cetrorelix 24(6) 155-8 |
|
cetuximab
|
| Erbitux - colorectal cancer (New drug) 28(4) 104-6 |
|
Champix
|
| see varenicline 31(1) 24-7 |
|
chancroid
|
| enoxacin - Enoxicin (New drug) 18(1) 7-9 |
|
charcoal, activated
|
| in doctor's bag supplies (PBAC question) 20(4) 86-7 |
| in poisoning 20(1) 14-6 |
|
chelating agents
|
| deferasirox - Exjade - iron overload (New drug) 29(4) 112-5 |
| deferiprone - thalassaemia - Ferriprox (New drug) 26(3) 68-71 |
|
chemotherapy, cancer - see antineoplastics
|
|
chest X-rays
|
| Pocket guide (book review) 27(6) 158 |
|
chickenpox
|
| varicella vaccine - frequently asked questions 28(1) 2-5 |
| letters 28(5) 113-5; 28(3) 55-8 |
|
child attention disorders
|
| letters 19(3) 59-62; 19(2) 36-8; 19(1) 3-6 |
| stimulant treatment 18(3) 60-3 |
|
children (see also infants)
|
| abnormal haematology laboratory results 27(3) 64-6 |
| abnormal laboratory results - paediatric biochemical tests 28(5) 126-9 |
| Aboriginal children - medication compliance (letter) 26(2) 27-9 |
| antidepressants and suicide risk (editorials) 28(5) 110-1; 28(5) 111-3 |
| letter 29(2) 32-5 |
| constipation management 25(4) 85-7 |
| letter 25(6) 131-2 |
| diagnosis and management of vulvovaginitis 28(4) 88-90 |
| discontinuation of naproxen suspension (letter) 25(5) 104-7 |
| drug regulation and prescribing (editorial) 26(6) 122-3 |
| letter 27(2) 28-33 |
| drug therapy in the 21st century (editorial) 23(1) 3 |
| 'Drugs and breastfeeding' (book review) 27(6) 154 |
| metronidazole (letter) 28(2) 29-33 |
| fever - paracetamol 23(3) 60-1 |
| consumer perspective 23(3) 61 |
| ibuprofen in fever (letter) 27(3) 55-7 |
| managing painful paediatric procedures 29(4) 94-6 |
| dental notes 29(4) 108 |
| letters 29(6) 149-50 |
| non-organic pain 22(5) 122-5 |
| obesity management 26(2) 30-2 |
| overdoses of over-the-counter drugs in infantile colic 29(3) 83 |
| over-the-counter medications 24(6) 149-51 |
| letters 26(5) 99-102; 25(2) 27-8 |
| overdoses of anticholinergic drugs in infantile colic 29(3) 83 |
| Paediatric pharmacopoeia - book review 26(2) 43 |
| phytomenadione - haemorrhagic disease of the newborn - Konakion (New formulation) 23(2) 45-6 |
| psychotropic drugs for children in general practice 28(5) 116-8 |
| rotavirus vaccine - Rotarix (New drug) 29(4) 112-5 |
| rotavirus vaccine - RotaTeq (New drug) 29(4) 112-5 |
| urinary tract infections 22(2) 40-3 |
| withdrawal of antiepileptic drugs from seizure-free children 29(1) 18-21 |
|
Chinese medicines
|
| quality and safety 26(6) 128-30 |
| letter 27(2) 28-33 |
|
chiral drugs
|
| pharmacology and efficacy 27(2) 47-9 |
| correction 28(3) 55-8 |
| letter 27(5) 109-13 |
|
Chirocaine
|
| see levobupivacaine 27(5) 131-3; 24(5) 129-31 |
|
chlamydia
|
| abnormal laboratory results 30(1) 8-13 |
|
chloramphenicol
|
| in conjunctivitis and aplastic anaemia (letters) 20(1) 3-4; 19(3) 59-62; 19(1) 3-6 |
|
chloroquine
|
| malaria and travel 25(3) 66-9 |
|
chlorpromazine
|
| in pregnancy and breastfeeding 30(6) 162-3 |
|
cholera
|
| inactivated cholera vaccine - Dukoral (New drug) 27(6) 159-65 |
| live cholera vaccine - Orochol (New drug) 23(4) 84-7 |
|
cholestasis
|
| flucloxacillin adverse reaction (editorial) 18(3) 54-6 |
| ursodeoxycholic acid - Ursofalk (New drug) 22(4) 95-8 |
|
cholesterol - see also hypercholesterolaemia; antilipidaemic drugs
|
| in diabetes 22(3) 67-9 |
| HDL cholesterol - laboratory results 17(4) 99-102 |
| HDL cholesterol - Sheffield tables 21(4) 98-9 |
|
chronic diseases
|
| chronic disease and travel 23(5) 107-9 |
|
chronic obstructive pulmonary disease - see pulmonary disease
|
|
Cialis
|
| see tadalafil 26(2) 46-7 |
|
ciclesonide
|
| Alvesco - asthma prophylaxis (New drug) 28(4) 104-6 |
| corticosteroid therapy in asthma 29(3) 63-6 |
|
cidofovir
|
| cytomegalovirus retinitis - Vistide (New drug) 22(2) 43-7 |
|
cilazapril
|
| antihypertensive - Inhibace (New drug) 20(2) 45-51 |
|
Ciloxan
|
| see ciprofloxacin 17(2) 30-2 |
|
cimetidine
|
| pharmacology 23(3) 57-9 |
|
cinacalcet
|
| Sensipar - hyperparathyroidism, hypercalcaemia (New drug) 28(3) 75-9 |
|
Cipramil
|
| see citalopram 21(2) 49-55 |
|
ciprofloxacin
|
| Ciprofloxacin-BC (New brand) 26(1) 22-3 |
| and fever (letter) 28(6) 136-9 |
| new formulation - Ciloxan 17(2) 30-2 |
| topical antibiotics and antibiotic resistance (letter) 24(2) 27-8 |
|
cisapride
|
| alternatives in gastrointestinal disorders 24(5) 110-2 |
| and arrhythmias 25(6) 135 |
| drug interactions 23(3) 59 |
| letter 23(5) 93-6 |
|
cisatracurium besylate
|
| neuromuscular blocker - Nimbex (New drug) 20(2) 45-51 |
|
citalopram
|
| Celapram (New strength) 27(1) 21-3 |
| citrates in renal calculi 19(4) 94-7 |
| serotonin reuptake inhibitor - Cipramil (New drug) 21(2) 49-55 |
| serotonin syndrome (medicinal mishap) 29(3) 71 |
|
cladribine
|
| hairy cell leukaemia - Leustatin (New drug) 18(2) 35-8 |
|
Clarinase
|
| see loratidine 23(1) 21-3 |
|
Clarinase Repetabs
|
| see loratidine 20(1) 22-3 |
|
clavulanic acid amoxycillin combination
|
| Augmentin - adverse effects 17(3) 55-6 |
|
climacteric
|
| management of menopause 17(1) 2-4 |
|
Climara
|
| see oestradiol 24(2) 43-7 |
|
Climen 28
|
| see cyproterone acetate combination 19(3) 81-3 |
| see oestradiol 24(2) 43-7 |
|
clinical intuition
|
| clinical intuition 25(1) 14-5 |
|
clinical pharmacology - see pharmacology
|
|
Clinical pharmacology essentials
|
| book review 24(4) 97 |
|
clinical tests - see abnormal laboratory results; diagnostic tests
|
|
clinical trials
|
| appraising medical research 29(5) 122-4 |
| development of new prescription drugs 29(6) 159-61 |
| hormone replacement therapy advice to patients 25(3) 60-2 |
| letters 25(5) 104-7 |
| interpretation 24(4) 78-9; 20(4) 93-6; 20(3) 61-4 |
| interpreting risks and ratios 31(1) 12-6 |
| pharmacotherapy for risk factors 30(2) 47-50 |
| risk factor pharmacotherapy (letter) 30(4) 88-90 |
|
clodronate
|
| hypercalcaemia of malignancy - Bonefos (New drug) 20(2) 45-51 |
|
clomipramine
|
| DBL Clomipramine (New brand) 23(2) 45-6 |
|
Clonac
|
| see diclofenac sodium 27(1) 21-3 |
|
clonazepam
|
| clinical use of antiepileptics 17(1) 9-12 |
| new brand - Paxam 20(1) 22-3 |
|
clopidogrel
|
| antiplatelet drug - Plavix (New drug) 22(2) 43-7 |
| antiplatelet therapy after coronary stents 30(4) 92-96 |
| interaction with warfarin 25(4) 81-5 |
|
Clopine
|
| see clozapine 27(1) 21-3 |
|
Clopixol-Acuphase
|
| see zuclopenthixol 19(2) 38-40 |
|
Clostridium botulinum type A toxin
|
| haemagglutinin complex - Dysport (New formulation) 24(2) 43-7 |
|
clozapine
|
| Clopine (New strength) 27(1) 21-3 |
| dopamine clinical pharmacology 17(2) 42-3 |
| new antipsychotic drugs 22(4) 81-3 |
|
coagulation disorders
|
| dental implications 18(2) 48 |
| laboratory results 18(2) 38-41 |
|
cocaine
|
| adverse effects 29(4) 109-11 |
|
Cochrane Airways Group Conference
|
| editorial 24(4) 78-9 |
|
codeine/ibuprofen
|
| Nurofen Plus (New combination) 25(4) 94-9 |
|
coeliac disease
|
| diagnostic tests 24(2) 38-40 |
| differential diagnosis (letter) 25(2) 27-8 |
| patient support organisations 24(2) 40-1 |
|
Cognex
|
| see tacrine 18(2) 35-8 |
|
cognition
|
| neurocognitive effects of chemotherapy 31(1) 22-4 |
|
cognitive behaviour therapy
|
| depression in medical illness 30(4) 86-8 |
| depression in old age 24(3) 65-7 |
| in general practice 24(2) 33-7 |
| management of mild depression in general practice 28(1) 8-10 |
| panic disorder 23(6) 124-6 |
| letters 24(2) 27-8 |
| patient support organisations 23(6) 128 |
| personal experience 23(6) 127-8 |
| treatment of non-depressive disorders 28(4) 91-3 |
|
cognitive testing
|
| mental status testing in dementia 28(1) 11-3 |
|
Colazide
|
| see balsalazide 28(4) 104-6 |
| letter 29(2) 32-5 |
|
colchicine
|
| management of gout 27(1) 10-3 |
|
colic, infantile
|
| overdoses of over-the-counter anticholinergic drugs 29(3) 83 |
|
colitis, ulcerative
|
| balsalazide - Colazide (New drug) 28(4) 104-6 |
| letter 29(2) 32-5 |
|
colonic diseases
|
| bowel preparation 28(1) 16-7 |
|
colonoscopy
|
| bowel preparation 28(1) 16-7 |
|
colorectal cancer
|
| angiogenesis inhibitors 29(1) 13-5 |
| arcitumomab - immunoscintigraphy - CEA-Scan (New drug) 26(3) 68-71 |
| bevacizumab - Avastin (New drug) 28(4) 104-6 |
| cetuximab - Erbitux (New drug) 28(4) 104-6 |
| clinical application of new drugs 25(5) 111-3 |
| folinic acid (PBAC question) 26(4) 77 |
| irinotecan - Camptosar (New drug) 21(2) 49-55 |
| oxaliplatin - Eloxatin (New drug) 24(3) 71-5 |
| letter 24(5) 107-9 |
| pharmacology of new drugs 25(5) 108-10 |
|
combination products
|
| combination products 24(5) 126; 24(5) 127-9 |
| letter 24(6) 135-6 |
| the polypill and cardiovascular disease (editorial) 28(4) 82-3 |
|
Combivent
|
| see ipratropium bromide 22(6) 147-51 |
|
complementary medicines
|
| 1907 Royal Commission on Secret Drugs, Cures and Foods 30(4) 91 |
| letter 30(6) 140-41 |
| agnus castus and premenstrual syndrome 24(5) 123 |
| antioxidants 22(6) 142-4 |
| celery seed tablets and thyroxine 24(1) 6-7 |
| Chinese medicines - quality and safety 26(6) 128-30 |
| letter 27(2) 28-33 |
| efficacy of Ginkgo biloba in tinnitus (editorial) 29(5) 120 |
| letter 30(2) 32-4 |
| glucosamine in osteoarthritis of the knee 27(3) 61-3 |
| letter 27(5) 109-13 |
| interactions with warfarin 25(3) 54-6 |
| letter 26(2) 27-9 |
| iodine in herbal cough mixture (letter) 24(3) 51-5 |
| regulation 21(4) 107-8 |
| regulation of advertising 27(5) 124-7 |
| safety (editorial) 25(3) 50-1 |
| safety - letter 26(2) 27-9 |
| saw palmetto - benign prostatic hypertrophy 23(4) 79 |
| St John's wort in depression 22(5) 112-3 |
| letter 23(1) 5 |
|
compliance - see patient compliance
|
|
computerised prescribing systems - see electronic prescribing
|
|
Comtan
|
| see entacapone 22(6) 147-51 |
|
Comvax
|
| see Haemophilus influenzae type b 23(3) 64-7 |
|
Concerta
|
| see methylphenidate 27(2) 50-1 |
|
condoms
|
| effects of chemicals, drugs 23(6) 129 |
|
confidence intervals
|
| interpreting risks and ratios 31(1) 12-6 |
|
congenital abnormalities - see birth defects
|
|
congestive heart failure - see heart failure, congestive
|
|
conjunctivitis
|
| chloramphenicol and aplastic anaemia (letters) 20(1) 3-4; 19(3) 59-62; 19(1) 3-6 |
| ketotifen - seasonal allergic conjunctivitis - Zaditen (New drug) 28(1) 19-23 |
| levocabastine - Livostin (New drug) 19(3) 81-3 |
| lodoxamide - Lomide (New drug) 21(2) 49-55 |
| management 17(3) 66-8 |
| ofloxacin - Ocuflox (New drug) 18(2) 35-8 |
| olopatadine - allergic seasonal conjunctivitis - Patanol (New drug) 25(6) 147-51 |
| sodium cromoglycate eye drops in conjunctivitis (PBAC question) 18(1) 12 |
|
connective tissue diseases
|
| corticosteroids 21(1) 9-11 |
|
Conn's syndrome
|
| see abnormal laboratory results 30(6) 147-9 |
|
consensus conference
|
| (editorial) 19(2) 30-4 |
| dental implications 19(4) 97 |
| consumer information about drugs 18(1) 10-1 |
| consumer product information (CPI) 18(1) 10-1 |
| consumer views 19(2) 30-4 |
| drug industry views 19(2) 30-4 |
| drugs and the internet 23(4) 73-4; 23(4) 75 |
| hypertension management (editorial) 17(2) 26-7 |
| medical practitioner's views 19(2) 30-4 |
| osteoporosis management (editorial) 20(4) 82-3 |
| letter 21(2) 31-4 |
| pharmacist views 19(2) 30-4 |
| stroke management 22(4) 85-7 |
|
constipation
|
| laxatives in aged care (PBAC question) 26(2) 30-2 |
| management in children 25(4) 85-7 |
| letter 25(6) 131-2 |
|
consumer - see also patient
|
|
consumer information
|
| Aboriginal patients 28(5) 123-5 |
| Adverse Medicine Events Line 28(4) 102; 27(2) 38 |
| aspirin and alcohol 28(1) 18-9 |
| letter 28(4) 84-7 |
| Consumer Medicine Information |
| dental requirements 25(4) 90 |
| doses missed by patients 25(1) 16-8 |
| progestogen-only contraceptives (letter) 25(3) 51-3 |
| editorial 26(1) 2-3 |
| utilisation 30(5) 122-4 |
| DIPEx patient experiences website review 25(4) 93-4 |
| direct-to-consumer advertising 27(1) 4-6 |
| drug labelling and packaging (letter) 28(1) 5-7 |
| letter 28(4) 84-7 |
| 'Health care and notions of risk' (book review) 27(6) 159 |
| hormone replacement therapy 25(3) 60-2 |
| letters 25(5) 104-7 |
| Media Doctor 28(1) 13 |
| overseas travel and medicines 29(3) 80-2 |
| pharmacotherapy for risk factors 30(2) 47-50 |
| publishing of drug evaluations (editorial) 29(5) 120 |
| letter 30(2) 32-4 |
| quality use of generic drugs (editorial) 27(4) 80-1 |
| letters 28(2) 29-33; 27(6) 138-41 |
| regulation of medicines advertising in Australia 27(5) 124-7 |
| role of patient support organisations 27(1) 19-21 |
| starter packs and drug samples 30(1) 14-16 |
| telephone information service 26(4) 87; 25(5) 115 |
|
consumers (see also patient's perspective)
|
| clinical intuition 25(1) 14-5 |
| direct drug advertising |
| letter 24(4) 80-2 |
| in New Zealand (editorial) 29(2) 30-2 |
| and drug advertising (editorial) 22(4) 74-5 |
| perceptions of risk 26(2) 44-5; 26(1) 20-1 |
| quality use of generic drugs (editorial) 27(4) 80-1 |
|
Continence Foundation of Australia
|
| patient support organisation 29(1) 24 |
|
contraceptives
|
| dienogest/ethinyloestradiol - Valette (New drug) 30(2) 50-55 |
| doses missed by users 25(1) 16-8 |
| letter 25(3) 51-3 |
| drospirenone/ethinyloestradiol - Yasmin (New drug) 25(6) 147-51 |
| effects of chemicals, drugs 23(6) 129 |
| etonogestrol - Implanon (New drug) 24(2) 43-7 |
| gestodene ethinyloestradiol combination - Femoden, Trioden, Minulet, Triminulet (New drug) 18(1) 7-9 |
| levonorgestrel - Mirena (New delivery system) 24(2) 43-7 |
| levonorgestrel - Postinor-2 (New strength) 25(4) 94-9 |
| overseas travel and medicines 29(3) 80-2 |
| in polycystic ovary syndrome 27(5) 129-31 |
| letter 28(3) 55-8 |
| progestogen-only methods 22(1) 6-8 |
| and rifampicin (letter) 23(2) 27-8 |
| risk of thromboembolism 25(3) 57-9 |
|
contrast media
|
| controlled clinical trials 20(4) 93-6; 20(3) 61-4 |
| disodium gadoxetate - Primovist - liver imaging (New drug) 29(3) 84-7 |
| effects on kidney 23(1) 17-9 |
| gadobenate dimeglumine - magnetic resonance imaging - MultiHance (New drug) 27(6) 159-65 |
| gadoteric acid - magnetic resonance imaging - Dotarem (New drug) 25(6) 147-51 |
| gadoteridol - magnetic resonance imaging - Prohance (New drug) 25(2) 44-7 |
| gadoversetamide - nuclear magnetic imaging - OptiMARK (New drug) 24(3) 71-5 |
| perflutren - ultrasound - Definity (New drug) 30(4) 107-11 |
|
Copaxone
|
| see glatiramer 27(5) 131-3; 22(6) 147-51 |
|
COPD - also see pulmonary disease, chronic obstructive
|
| in primary care - book review 27(1) 13 |
|
Corolan
|
| see ivabradine 30(2) 50-55 |
|
coronary angioplasty
|
| abciximab - ReoPro (New drug) 19(3) 81-3 |
| antiplatelet drugs 19(4) 98-101 |
|
coronary disease (see also angina; myocardial infarction)
|
| antiplatelet therapy after coronary stents 30(4) 92-96 |
| cardiac markers - abnormal laboratory results 26(4) 88-90 |
| and diabetes 22(3) 67-9 |
| HDL cholesterol - laboratory results 17(4) 99-102 |
| HDL cholesterol - Sheffield tables 21(4) 98-9 |
| management 24(3) 56-8 |
| positron emission tomography 18(1) 13-5 |
| thallium scanning 17(3) 57-61 |
| and travel 23(5) 107-9 |
|
coronary intervention, percutaneous
|
| antiplatelet therapy after coronary stents 30(4) 92-96 |
| bivalirudin - anticoagulant - Angiomax (New drug) 28(3) 75-9 |
|
corticosteroids
|
| in aspiration pneumonia 26(1) 14-7 |
| in asthma 29(3) 63-6 |
| in asthma - Cochrane Airways Group conference (editorial) 24(4) 78-9 |
| autoimmune diseases 22(1) 9-11 |
| beta agonist combination inhalers in asthma 28(2) 26-8 |
| budesonide - Crohn's disease - Entocort (New formulation) 22(1) 20-3 |
| childhood asthma (editorials) 20(3) 54-5; 20(3) 56-7 |
| in chronic obstructive pulmonary disease 30(3) 64-7; 24(6) 152-5 |
| letter - alpha-1-antitrypsin deficiency 30(6) 140-41 |
| ciclesonide - Alvesco - asthma prophylaxis (New drug) 28(4) 104-6 |
| clinical pharmacology in asthma 19(2) 44-7 |
| in croup 20(4) 99-101 |
| in dermatology 21(1) 9-11 |
| dental implications |
Home